FDA OKs Long-Acting Risperidone; TMS for Anxious Depression; CBT Bests Pharma
(MedPage Today) -- The FDA approved the biweekly long-acting injectable (LAI) risperidone (Rykindo) for the treatment of schizophrenia and bipolar I disorder, Luye Pharma Group announced.
A phase IIa study showed a significantly greater improvement...
Source: MedPage Today Psychiatry - Category: Psychiatry Source Type: news
More News: Bipolar | Depression | Mania | Pharmaceuticals | Psychiatry | Risperdal Consta | Schizophrenia | Study